semaglutide compounding news november 2025 The FDA announced that #semaglutide is no longer in shortage. That means pharmacies like ours won't be able to compound them after April 22nd. Make sure you talk to your provider November 2025 Drug Safety: Recalls

doi: 10.23937/2378-3656/1410150 Summary Keywords euglycemic diabetic ketoacidosis (euDKA), SGLT-2 inhibitor, GLP-1 receptor agonist, type 2 diabetes mellitus, adverse drug reaction Citation Gandecka-Pempera A, Naskrt D, Adamska A and Zozuliska-Zikiewicz D (2025) Severe euglycemic ketoacidosis following combined therapy with GLP-1 receptor agonist and SGLT-2 inhibitor, refractory to standard treatment: a case report

The medication's pharmacokineticshow your body absorbs, distributes, and eliminates itremain stable regardless of your meal status

Practical checklist before considering use Dose: No validated human dosing exists

Stimulation of Insulin Secretion : Semaglutide raises the level of blood and brings about an increase in secretion from the pancreas

Available at: Henney AE, Wilding JPH, Alam U, Cuthbertson DJ